This company is engaged in the development,_manufacture, and commercialisation of novel botulinum toxin products for various aesthetic and therapeutic applications. It was_formerly_known as ORGANIZATION ORGANIZATION ORGANIZATION. It was_founded by PERSON_PERSON,_PERSON_PERSON, and PERSON_PERSON in DATE. The registered_business office of the company is located in CITY, COUNTRY COUNTRY COUNTRY COUNTRY. The company 's lead product TITLE is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical_trials for the treatment of crow 's feet lines ; has completed initial Phase_NUMBER clinical_trials for the treatment of hyperhidrosis and for the prevention of migraine headaches ; and has completed Phase I clinical_trials for the treatment of other indications, such_as neuropathic pain and rhinitis. It also develops RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the NUMBER NUMBER NUMBER Phase I_/ NUMBER clinical dose escalation trials for the treatment of glabellar lines.